BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) to report its financial ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $145.00. The company’s shares closed last ...

BioNTech SE, a biotechnology company ... and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March ...

with BNT211 in solid tumors. While oncology is still central to BioNTech's pipeline, BioNTech's expert knowledge of mRNA easily lends itself to the development of vaccines for viral infections ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...

About BioNTech SE - ADR and Legend Biotech Corp (ADR ... and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase ...

In April 2024, the British drugmaker filed a similar complaint against Pfizer and BioNTech over their alleged infringement of protected mRNA vaccine technologies. At the time, GSK claimed that the ...

The lawsuits add to a web of U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their COVID vaccines, including one brought by Moderna against ...

The Moderna lawsuits echo similar claims made by GSK when it sued Pfizer and BioNTech for allegedly infringing upon the company’s mRNA patents back in April. At the time, Pfizer voiced ...